Eclipse Regenesis

Executive Summary

Eclipse Regenesis is a clinical-stage biotechnology company developing the Eclipse XL1 System, a novel device-based regenerative therapy for Short Bowel Syndrome (SBS). SBS is a devastating condition resulting from massive intestinal resection, leading to severe malabsorption and dependence on lifelong parenteral nutrition (PN) or intestinal transplantation. The Eclipse XL1 System mechanically stimulates the patient's own intestine to induce the growth of new, functional tissue, potentially restoring absorptive capacity and freeing patients from PN. This approach offers a non-pharmacological, autologous alternative that could significantly improve quality of life and reduce healthcare costs.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial results60% success
• Q2 2026FDA Breakthrough Device designation70% success
• Q3 2026Strategic partnership for commercialization50% success